

Dationt's Names

Carvykti

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Doto.

Patient's Date of Birth:
NDI#.
NIDI#.
NPI#:
Physician Office Fax:
r
NPI#:
Phone:
☐ Same as Requesting Provider
NPI#:
Phone:
n accordance with FDA-approved labeling,
n accordance with FDA-approved labeling, dence-based practice guidelines.

Criteria Questions:
1. Has the patient previously received one complete treatment course of Carvykti or another chimeric antigen
(CAR) T-cell therapy directed at any target (e.g., Abecma, Yescarta)?
☐ Yes, Continue to 2 ☐ No, Continue to 2
100, Continue to 2
2. What is the diagnosis?
☐ Multiple myeloma, <i>Continue to 3</i>
☐ Other, please specify, <i>Continue to 3</i>
3. What is the clinical setting in which the requested drug will be used?
☐ Relapsed disease, Continue to 4
☐ Refractory disease, <i>Continue to 4</i>
☐ Other, please specify Continue to 4
4. Has the patient received at least one prior line of therapy for multiple myeloma, including at least one medication from each of the following categories: A) proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib) and B) immunomodulatory agent (e.g., lenalidomide, pomalidomide)? <i>ACTION REQUIRED</i> : If Yes, attach supporting chart note(s). ☐ Yes, <i>Continue to 5</i> ☐ No, <i>Continue to 5</i>
 5. Is the disease lenalidomide-refractory? ☐ Yes, Continue to 6 ☐ No, Continue to 6
6. Does the patient have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (patient is ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours)? ☐ Yes, Continue to 7 ☐ No, Continue to 7
7. Does the patient have adequate and stable kidney, liver, pulmonary and cardiac function? ☐ Yes, <i>Continue to 8</i> ☐ No, <i>Continue to 8</i>
8. Does the patient have known active or prior history of central nervous system (CNS) involvement, including CNS multiple myeloma? ☐ Yes, Continue to 9 ☐ No, Continue to 9
 9. Does the patient have clinically significant active infection? ☐ Yes, Continue to 10 ☐ No, Continue to 10
10. Does the patient have active graft versus host disease? ☐ Yes, Continue to 11 ☐ No, Continue to 11

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Carvykti SGM 5256-A -01/2025.

(Prescriber or Authorized Signature	Date (mm/dd/yy)
attest that this information is accurate and true, and that docu nformation is available for review if requested by CVS Careman	
years of age, No Further Questions	
12. What is the patient's age (in years)?	
□ No, Continue to 12	
☐ Yes, Continue to 12	
11. Does the patient have an active inflammatory disorder?	